Private Trust Co Na buys $5,772,403 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Private Trust Co Na scooped up 3,704 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 19, 2016. The investment management firm now holds a total of 91,033 shares of AbbVie Inc which is valued at $5,772,403.AbbVie Inc makes up approximately 1.46% of Private Trust Co Na’s portfolio.

Other Hedge Funds, Including , Handelsbanken Fonder Ab reduced its stake in ABBV by selling 23,500 shares or 3.31% in the most recent quarter. The Hedge Fund company now holds 687,112 shares of ABBV which is valued at $43,672,839. AbbVie Inc makes up approx 1.73% of Handelsbanken Fonder Ab’s portfolio. Stillwater Capital Advisors sold out all of its stake in ABBV during the most recent quarter. The investment firm sold 195,364 shares of ABBV which is valued $12,653,726.West Oak Capital boosted its stake in ABBV in the latest quarter, The investment management firm added 407 additional shares and now holds a total of 14,882 shares of AbbVie Inc which is valued at $954,829. AbbVie Inc makes up approx 0.68% of West Oak Capital’s portfolio.Marshwinds Advisory Co boosted its stake in ABBV in the latest quarter, The investment management firm added 750 additional shares and now holds a total of 26,086 shares of AbbVie Inc which is valued at $1,673,678. AbbVie Inc makes up approx 0.81% of Marshwinds Advisory Co’s portfolio.

AbbVie Inc opened for trading at $63.57 and hit $63.9 on the upside on Wednesday, eventually ending the session at $63.41, with a gain of 0.14% or 0.09 points. The heightened volatility saw the trading volume jump to 75,02,821 shares. Company has a market cap of $102,557 M.

On the company’s financial health, AbbVie Inc reported $1.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.14. The company had revenue of $5958.00 million for the quarter, compared to analysts expectations of $5978.41 million. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.